In contrast, DPP-4 inhibitor users had no elevated risk of colorectal cancer incidence in diabetic patients [122], and that the DPP-4 inhibitor was also associated with a significantly reduced risk of colorectal cancer among T2DM patients [123]. This evidence concerns the gene DPP4 and colorectal cancer.